189 related articles for article (PubMed ID: 26788616)
1. Idiopathic pulmonary fibrosis: the role of the pharmacy benefit manager in providing access to effective, high-value care.
Morrow TJ
Am J Manag Care; 2015 Oct; 21(14 Suppl):s294-301. PubMed ID: 26788616
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
3. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
Dempsey TM; Thao V; Moriarty JP; Borah BJ; Limper AH
BMC Pulm Med; 2022 Jan; 22(1):18. PubMed ID: 35000589
[TBL] [Abstract][Full Text] [Related]
5. Health economic evaluation in idiopathic pulmonary fibrosis in France.
Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
[TBL] [Abstract][Full Text] [Related]
6. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
[TBL] [Abstract][Full Text] [Related]
8. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
9. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
10. Evaluating new treatment options.
Nathan SD
Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
12. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
Glassberg MK
Am J Manag Care; 2019 Jul; 25(11 Suppl):S195-S203. PubMed ID: 31419091
[TBL] [Abstract][Full Text] [Related]
13. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe.
Duck A; Pigram L; Errhalt P; Ahmed D; Chaudhuri N
Adv Ther; 2015 Feb; 32(2):87-107. PubMed ID: 25691376
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
Raghu G; Selman M
Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
[No Abstract] [Full Text] [Related]
16. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
[TBL] [Abstract][Full Text] [Related]
17. Management of Idiopathic Pulmonary Fibrosis.
Pleasants R; Tighe RM
Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
[No Abstract] [Full Text] [Related]
18. Improving outcomes and managing costs in idiopathic pulmonary fibrosis.
Morrow T
Am J Manag Care; 2019 Jul; 25(11 Suppl):S204-S209. PubMed ID: 31419090
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic pulmonary fibrosis: an update.
Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
[TBL] [Abstract][Full Text] [Related]
20. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
